Cantor Fitzgerald Comments on ARCT FY2025 Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for Arcturus Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the biotechnology company will post earnings of ($3.21) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.31) per share.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The business had revenue of $41.67 million for the quarter, compared to analysts’ expectations of $49.16 million. During the same quarter in the previous year, the firm posted ($0.61) EPS.

Separately, HC Wainwright reiterated a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research report on Monday, January 13th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $66.75.

Arcturus Therapeutics Stock Performance

NASDAQ:ARCT opened at $16.69 on Thursday. The business’s fifty day moving average is $17.32 and its 200 day moving average is $19.76. The firm has a market cap of $452.13 million, a price-to-earnings ratio of -7.53 and a beta of 2.63. Arcturus Therapeutics has a 52-week low of $14.30 and a 52-week high of $45.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ARCT. SG Americas Securities LLC raised its stake in Arcturus Therapeutics by 45.0% in the fourth quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock valued at $203,000 after purchasing an additional 3,705 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its position in shares of Arcturus Therapeutics by 139.7% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 82,057 shares of the biotechnology company’s stock valued at $1,393,000 after buying an additional 47,824 shares in the last quarter. Nordea Investment Management AB raised its position in shares of Arcturus Therapeutics by 3.7% during the 4th quarter. Nordea Investment Management AB now owns 65,778 shares of the biotechnology company’s stock valued at $1,097,000 after buying an additional 2,335 shares in the last quarter. Franklin Resources Inc. grew its position in Arcturus Therapeutics by 54.6% in the third quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company’s stock worth $2,412,000 after acquiring an additional 36,714 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Arcturus Therapeutics by 1.1% during the third quarter. Geode Capital Management LLC now owns 551,798 shares of the biotechnology company’s stock valued at $12,810,000 after purchasing an additional 5,789 shares in the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.